GlassScriptPhysician profile
Molly C Reeves
NPI 1912356858
$158,239.92
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25K · 2022: $65K · 2023: $50K · 2024: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $24K · Food and Beverage: $7,623 · Consulting Fee: $1,400 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,756.50 |
| Travel and Lodging | $24,379.93 |
| Food and Beverage | $7,622.54 |
| Consulting Fee | $1,400.00 |
| Education | $104.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,985.29 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $37,060.74 | 2021-2023 | Tremfya, Simponi Aria, Stelara |
| Janssen Biotech, INC. | $32,679.97 | 2021-2024 | Simponi Aria, Tremfya |
| Amgen INC. | $16,628.99 | 2021-2024 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,001.13 | 2021-2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $813.42 | 2021-2024 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $733.20 | 2021-2024 | Acthar |
| Glaxosmithkline, LLC. | $677.36 | 2021-2024 | Benlysta |
| Pfizer INC. | $630.63 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $515.40 | 2021-2024 | |
| Lilly USA, LLC | $448.22 | 2021-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $439.85 | 2022-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $338.00 | 2021 | |
| Aurinia Pharma U.S., INC. | $229.86 | 2021-2023 | Lupkynis |
| Radius Health, INC. | $227.22 | 2021-2024 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $182.41 | 2021-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $161.68 | 2022-2024 | Strensiq |
| Sobi, INC | $147.40 | 2022-2023 | |
| Horizon Therapeutics Plc | $82.68 | 2022-2023 | Krystexxa |
| Tersera Therapeutics LLC | $42.78 | 2022 | |
| Scilex Pharmaceuticals INC. | $40.44 | 2024 | |
| Hikma Pharmaceuticals USA | $28.09 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.33 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $24.15 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.30 | 2022 | |
| Fresenius Kabi USA, LLC | $18.60 | 2024 | Idacio |
| Antares Pharma, INC. | $15.22 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.91 | 2022 | |
| Genentech USA, INC. | $14.53 | 2024 | Actemra |
| Kiniksa Pharmaceuticals, LTD. | $13.12 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Reeves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.